Ascendis Pharma's Q2 Revenue Driven by Strong Demand for Hypoparathyroidism Drug Yorvipath, Bank of America Says

MT Newswires Live

Aug 08, 2025

Ascendis Pharma's (ASND) Q2 revenue gains appear to have been driven by growing adoption of Yorvipath to treat hypoparathyroidism in adults, Bank of America Securities said in a note to clients Thursday.

The brokerage now expects Ascendis to have a 2025 loss of 3.26 euros ($3.80) per share; in 2026 earnings of 2.67 euros per share, and in 2027 earnings of 10.06 euros per share, on 2025 revenue of 753.4 million euros, 2026 revenue of 1.21 billion euros, and 2027 revenue of 1.80 billion euros.

Bank of America now expects Yorvipath revenue for 2025 at 499 million euros, for 2026 at 806 million euros, and 2027 at 1.2 billion euros.

While the company's revenue from Skytrofa, to treat growth hormone deficiency, missed Q2 analysts' estimates, the recent US Food and Drug Administration approval for use in adults could translate to a long-term growth driver. However, Bank of America's analysts lowered its peak sales forecast for Skytrofa to 520 million euros from 626 million euros previously.

The brokerage said it reiterated its buy rating on the stock and raised its price target to $227 per share from $217.

Price: 179.93, Change: -10.42, Percent Change: -5.47

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2557575356"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557575356\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557575356?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-08 23:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557575356","market":"fut","top_or_hot":-1,"title":"Ascendis Pharma's Q2 Revenue Driven by Strong Demand for Hypoparathyroidism Drug Yorvipath, Bank of America Says","media":"MT Newswires Live","content":"<html><body><p> Ascendis Pharma's (ASND) Q2 revenue gains appear to have been driven by growing adoption of Yorvipath to treat hypoparathyroidism in adults, Bank of America Securities said in a note to clients Thursday.</p><p>The brokerage now expects Ascendis to have a 2025 loss of 3.26 euros ($3.80) per share; in 2026 earnings of 2.67 euros per share, and in 2027 earnings of 10.06 euros per share, on 2025 revenue of 753.4 million euros, 2026 revenue of 1.21 billion euros, and 2027 revenue of 1.80 billion euros.</p><p>Bank of America now expects Yorvipath revenue for 2025 at 499 million euros, for 2026 at 806 million euros, and 2027 at 1.2 billion euros.</p><p>While the company's revenue from Skytrofa, to treat growth hormone deficiency, missed Q2 analysts' estimates, the recent US Food and Drug Administration approval for use in adults could translate to a long-term growth driver. However, Bank of America's analysts lowered its peak sales forecast for Skytrofa to 520 million euros from 626 million euros previously.</p><p>The brokerage said it reiterated its buy rating on the stock and raised its price target to $227 per share from $217.</p><p>Price: 179.93, Change: -10.42, Percent Change: -5.47</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascendis Pharma's Q2 Revenue Driven by Strong Demand for Hypoparathyroidism Drug Yorvipath, Bank of America Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscendis Pharma's Q2 Revenue Driven by Strong Demand for Hypoparathyroidism Drug Yorvipath, Bank of America Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-08 23:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Ascendis Pharma's (ASND) Q2 revenue gains appear to have been driven by growing adoption of Yorvipath to treat hypoparathyroidism in adults, Bank of America Securities said in a note to clients Thursday.</p><p>The brokerage now expects Ascendis to have a 2025 loss of 3.26 euros ($3.80) per share; in 2026 earnings of 2.67 euros per share, and in 2027 earnings of 10.06 euros per share, on 2025 revenue of 753.4 million euros, 2026 revenue of 1.21 billion euros, and 2027 revenue of 1.80 billion euros.</p><p>Bank of America now expects Yorvipath revenue for 2025 at 499 million euros, for 2026 at 806 million euros, and 2027 at 1.2 billion euros.</p><p>While the company's revenue from Skytrofa, to treat growth hormone deficiency, missed Q2 analysts' estimates, the recent US Food and Drug Administration approval for use in adults could translate to a long-term growth driver. However, Bank of America's analysts lowered its peak sales forecast for Skytrofa to 520 million euros from 626 million euros previously.</p><p>The brokerage said it reiterated its buy rating on the stock and raised its price target to $227 per share from $217.</p><p>Price: 179.93, Change: -10.42, Percent Change: -5.47</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ASND","symbol_name":"Ascendis Pharma A/S","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2557575356","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557575356","pubTimestamp":1754666075,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ascendis Pharma's  Q2 revenue gains appear to have been driven by growing adoption of Yorvipath to treat hypoparathyroidism in adults, Bank of America Securities said in a note to clients Thursday.The brokerage now expects Ascendis to have a 2025 loss of 3.26 euros  per share; in 2026 earnings of 2.67 euros per share, and in 2027 earnings of 10.06 euros per share, on 2025 revenue of 753.4 million euros, 2026 revenue of 1.21 billion euros, and 2027 revenue of 1.80 billion euros.Bank of America now expects Yorvipath revenue for 2025 at 499 million euros, for 2026 at 806 million euros, and 2027 at 1.2 billion euros.While the company's revenue from Skytrofa, to treat growth hormone deficiency, missed Q2 analysts' estimates, the recent US Food and Drug Administration approval for use in adults could translate to a long-term growth driver. However, Bank of America's analysts lowered its peak sales forecast for Skytrofa to 520 million euros from 626 million euros previously.The brokerage said","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ASND":"Ascendis Pharma A/S"},"translate_title":"美国银行表示，Ascendis Pharma第二季度收入受到甲状旁腺功能减退药物Yorvipath强劲需求的推动","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASND":0.9},"content_text":"Ascendis Pharma's (ASND) Q2 revenue gains appear to have been driven by growing adoption of Yorvipath to treat hypoparathyroidism in adults, Bank of America Securities said in a note to clients Thursday.The brokerage now expects Ascendis to have a 2025 loss of 3.26 euros ($3.80) per share; in 2026 earnings of 2.67 euros per share, and in 2027 earnings of 10.06 euros per share, on 2025 revenue of 753.4 million euros, 2026 revenue of 1.21 billion euros, and 2027 revenue of 1.80 billion euros.Bank of America now expects Yorvipath revenue for 2025 at 499 million euros, for 2026 at 806 million euros, and 2027 at 1.2 billion euros.While the company's revenue from Skytrofa, to treat growth hormone deficiency, missed Q2 analysts' estimates, the recent US Food and Drug Administration approval for use in adults could translate to a long-term growth driver. However, Bank of America's analysts lowered its peak sales forecast for Skytrofa to 520 million euros from 626 million euros previously.The brokerage said it reiterated its buy rating on the stock and raised its price target to $227 per share from $217.Price: 179.93, Change: -10.42, Percent Change: -5.47","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}